Insider · CIK 0001651537
Mark Erlander
Files at CRDF (Cardiff Oncology, Inc.). First filing -, latest -.
In brief
Mark Erlander files SEC Form 4 as CEO and director at CRDF (Cardiff Oncology, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Mark Erlander has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 11, 2025 | CRDF Cardiff Oncology, Inc. | AGrant or award Stock Optionsderivative | +758,400 | $0.00 | $0 | 2,925,098 | Mar 13, 2025 |
| Mar 7, 2024 | CRDF Cardiff Oncology, Inc. | AGrant or award Stock Optionsderivative | +510,000 | $0.00 | $0 | 2,170,310 | Mar 7, 2024 |
Questions about Mark Erlander
Answered from the filings on this page, as of the latest one.
Is Mark Erlander buying or selling?
Mark Erlander has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Mark Erlander's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Mark Erlander has 0.
Where does Mark Erlander file Form 4?
Mark Erlander has filed Form 4 at CRDF (Cardiff Oncology, Inc.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.